HLA-C and neoplasm: DeepHLApan, incorporated in TSNAD v2.0 and tumor-specific neoantigen database (TSNAdb; v2.0), combines predicting peptide–MHC binding affinity and immunogenicity together, thus providing more options for neoantigen selection [68,141,142].